UW spinout Opticyte lands $4.6M to test device that quickly detects early signs of organ failure
January 12, 2021 at 3:55 pm
Lori Arakaki, Opticyte co-founder and CEO. (Opticyte Photo)
University of Washington biotech spinout Opticyte has landed $2.9 million in federal grants and $1.7 million in seed funding. The Seattle startup is developing a non-invasive technology that can detect oxygen levels in cells in real time.
The Opticyte Cell O
2 Monitor could help in the treatment of sepsis, which is an infection that runs amuck and can cause organs to shut down, resulting in death. If a sepsis patient sees their cellular oxygen levels drop, it can be an indication of the onset of organ failure.